Kristian Holgersson is a Swedish cancer researcher who decided to pursue a career in cancer research after the loss of his father in lung cancer. After completing a Bachelor of Science in the U.S. he went back to his country of origin, Sweden, to work as a pre-doctoral research fellow at Karolinska Institute in Stockholm. There he was trained under Dr. Yihai Cao, one of the pioneers in cancer angiogenesis for two years. In the lab of Dr. Cao he contributed to the discovery of the involvement of circadian disruptions in the tumor microenvironment. While being in Sweden Kristian got the idea that the acidic nature of tumors may have a systemic effect on the heart explaining cancer-related deaths in many cases. He then decided to pursue this idea as a PhD project returning to the U.S. He began to collaborate with radiation oncologist and professor Dr. Reinhard Schulte who pointed out that the results seen in the RTOG0617 trial could partly be explained by the idea of Kristian Holgersson. Kristian would rapidly advance with pre-clinical results giving support to the idea and has already won two prizes by the Loma Linda University School of Medicine. In September of 2024 he is going to present the project for the first time at American Society for Radiation Oncology in Walter E. Washington Convention Center, Washington D.C.
Disclosures:
- Employment: none
- Compensation: none
- Ownership: none
- Leadership: none